title: Metrics survey of industry-sponsored clinical trials in Canada and comparator jurisdictions between 2005 and 2010.
abstract: Industry-sponsored clinical trials play a key role in the development of therapies. This survey suggests that between 2005 and 2010, research-based pharmaceutical firms worldwide initiated fewer trials and recruited fewer subjects annually. In contrast, at the country level, the clinical trial activity of such firms increased in emerging countries and in Japan. Canada's trend in the number of new trials followed that of the global industry, but the trend in new sites and newly recruited subjects fell below the global rate. Informal comparisons point to potential issues for Canada in such areas as site capacity, cost per subject and time to first subject-in. When compared to certain Western European countries and the United States, Canada remained well positioned on a number of metrics. Nonetheless, Canada faces mounting challenges from both traditional locations and emerging countries and may require coordinated efforts to remain a place of choice to conduct trials.
authors: Hôpital Ste-Justine, Montreal, QC, Former Sr. VP, Clinical and Regulatory Affairs and Chief Scientific Officer, Novartis Pharmaceuticals Canada Inc., Dorval, QC.
authors: Jean-Marie
authors: JM
authors: Leclerc
authors: Normand
authors: N
authors: Laberge
authors: Jean
authors: J
authors: Marion
mesh_terms: D002170:Canada / Q000453:epidemiology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D003625:Data Collection; D004345:Drug Industry / Q000706:statistics & numerical data*; D005062:European Union / Q000706:statistics & numerical data; D006801:Humans; D014481:United States / Q000453:epidemiology
references: J Clin Oncol. 2008 Mar 20;26(9):1479-82
references: 18349399
references: CMAJ. 2011 Nov 8;183(16):E1179
references: 21969412
references: N Engl J Med. 2009 Feb 19;360(8):816-23
references: 19228627
references: N Engl J Med. 2010 Oct 21;363(17):1591-3
references: 20942660
references: CMAJ. 2009 Mar 17;180(6):603-6
references: 19289801
references: Nat Rev Drug Discov. 2011 May;10(5):321-2
references: 21532547